The Effect of Vitamin D Supplement Consumption on Premenstrual Syndrome in Vitamin D-Deficient Young Girls: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.

Plain-language guide to PMID 31104056 (2019): double-blind randomized controlled trial of Vitamin D, K2, Magnesium and Zinc and Copper (Supplement).

Key Facts

PMID: 31104056
Journal: Complementary medicine research
Year: 2019
Study type: Randomized Controlled Trial
Authors: Abdollahi R et al. (5 authors)
DOI: 10.1159/000500016

What This Study Did, in Plain Language

What Was Tested

Researchers studied Vitamin D, K2, Magnesium and Zinc and Copper (Supplement) in this randomized controlled trial publication.

The aim of this study was to evaluate the effect of vitamin D supplementation in the treatment of PMS in vitamin D-deficient young girls.

Why It Was Studied

Premenstrual syndrome (PMS) alludes to a cyclic advent of somatic and psychiatric symptoms that affect some women of reproductive age.

Who Took Part

The age groups tagged for this paper are teenagers, young adults and adults, women only.

At the beginning and at the end of week 12, serum 25(OH)-D, premenstrual symptoms, anthropometric indices, dietary intake, physical activity level, and sun exposure were evaluated.

How the Study Was Run

In design terms this was a randomized, double-blind and placebo-controlled study.

The participants were allocated by chance, so the Vitamin D, K2, Magnesium and Zinc group and the comparison group should start out alike.

Blinding on both sides kept the participants and researchers unaware of who received Vitamin D, K2, Magnesium and Zinc.

Some participants received a placebo instead of Vitamin D, K2, Magnesium and Zinc, giving a reference point.

What Was Measured

PubMed files the paper under topics including Dietary Supplements, Premenstrual Syndrome, Vitamin D and Vitamin D Deficiency.

Author keywords: PSST questionnaire and Young girls.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc and Copper (Supplement).

Results are reported in around 5 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2019 (Complementary medicine research), a journal based in Switzerland.

More context: the Vitamin D, K2, Magnesium and Zinc compound page and the Copper (Supplement) compound page, all human trials.

Our Notes on the Compounds

Vitamin D, K2, Magnesium and Zinc: Magnesium is described as required for AMPK to function.

Copper (Supplement): The active site of cytochrome c oxidase is described as containing copper ions that are essential for electron transfer.

Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.